Gracecast Lung Cancer Audio

Drs. Ben Solomon (Peter MacCallum Cancer Center in Melbourne) and Ross Camidge (Univ. of Colorado) answer Qs on ALK rearrangements and crizotinib (XALKORI) for advanced non-small cell lung cancer (NSCLC).

Dr. Ross Camidge reviews considerations of who to screen for an ALK rearrangement and additional treatment alternatives for patients with ALK-positive advanced non-small cell lung cancer.

Dr. Ben Solomon of Peter MacCallum Cancer Centre in Melbourne Australia reviews ALK Inhibition from mechanism of action to activity and side effect profile of crizotinib, newly approved for patients with ALK-positive advanced non-small cell lung cancer.

Dr. Rogerio Lilenbaum, lung cancer expert, medical oncologist, & Chairman of Cleveland Clinic Florida, answers questions on special management considerations for elderly and frail patients with lung cancer.

Dr. Rogerio Lilenbaum, medical oncologist and Chair of Heme/Onc at Cleveland Clinic in Weston, FL, reviews evidence on how age and other medical problems should be incorporated into management of lung cancer.

Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC,  answers questions on management of side effects related to skin, hair, and nails for patients on cancer treatments that cause dermatologic complications.

Case-based discussion with multiple lung cancer experts on the controversial question of whether to recommend consolidation chemotherapy after concurrent chemotherapy and radiation for locally advanced NSCLC.

Question and answer session with Drs. Mary Pinder-Schenck from Moffitt Cancer Center in Tampa and Nasser Hanna from Indiana University about highlights in lung cancer from ASCO 2011 annual meeting.

Dr. Nasser Hanna from Indiana University Cancer Center reviews highlights of presentations on advanced/metastatic NSCLC from the ASCO 2011 annual meeting.

Dr. Mary Pinder-Schenck from the H. Lee Moffitt Cancer Center in Tampa, FL reviews highlights of presentations on small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma from the ASCO 2011 meeting.

Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.

Case-based discussion with multiple lung cancer experts on whether to recommend post-operative (adjuvant) chemotherapy for a patient with a less than 4 cm non-small cell lung cancer (NSCLC) tumor with some high risk features.

Case-based discussion with multiple lung cancer experts on whether to recommend post-operative (adjuvant) chemotherapy for a patient with small non-small cell lung cancer (NSCLC) tumor with satellite lesions.

Question and answer session with Dr. Minesh Mehta, Professor of Radiation Oncology at Northwestern University, on topics related to treatments for brain metastases and related complications, especially in the setting of lung cancer.

Dr. Minesh Mehta, Professor of Radiation Oncology at Northwestern University, describes benefits and risks of multiple interventions that are currently used or being studied to reduce risk of developing brain metastases or treat established metastases.

Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.

Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.

Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.

Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.

Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.